Table 4.
Systemic inflammatory profile after 7 weeks of intervention, stratified by intervention group, intention-to-treat analysis
| Mean difference (std) between RP and baseline (pg/mL) | |||
|---|---|---|---|
| Cytokines | Placebo (n = 63) * | MAG-EPA (n = 63) * | p-value |
| IL-1b | -0.27 (0.38) | -0.30 (0.45) | 0.66 † |
| IL-1ra | -18.69 (46.46) | -13.41 (65.11) | 0.50 † |
| IL-2 | -1.07 (1.35) | -0.85 (1.35) | 0.32 † |
| IL-4 | -0.40 (0.55) | -0.26 (0.62) | 0.20 ** |
| IL-5 | -1.04 (2.07) | -0.89 (4.53) | 0.13 † |
| IL-6 | -0.27 (0.80) | 1.69 (13.37) | 0.14 † |
| IL-7 | -0.85 (1.87) | 0.04 (2.35) | 0.026 † |
| IL-8 | -0.64 (1.99) | 1.01 (10.84) | 0.15 † |
| IL-9 | 2.35 (23.88) | -1.88 (64.40) | 0.73 † |
| IL-10 | -0.38 (0.71) | -0.42 (1.12) | 0.88 † |
| IL-12p70 | -0.39 (0.77) | -0.75 (3.37) | 0.87 † |
| IL-13 | -0.92 (1.23) | -1.02 (1.27) | 0.62 † |
| IL-15 | -0.11 (2.32) | 4.33 (30.85) | 0.41 † |
| IL-17 | -0.55 (1.62) | -0.56 (2.15) | 0.46 † |
| Eotaxin | -4.58 (9.56) | -2.98 (10.51) | 0.37 ** |
| bFGF | -5.30 (9.69) | -5.95 (10.11) | 0.57 † |
| G-CSF | -3.07 (13.72) | 1.98 (15.02) | 0.06 † |
| GM-CSF | -0.19 (0.62) | 0.13 (3.57) | 0.55 † |
| INFg | -0.98 (1.27) | -2.85 (15.09) | 0.63 † |
| MCP-1 | -2.15 (4.74) | -0.31 (4.47) | 0.06 † |
| MIP-1a | -0.05 (0.29) | -0.07 (0.54) | 0.94 † |
| MIP-1b | 7.41 (22.41) | 6.88 (21.34) | 0.56 † |
| TNFa | -3.23 (6.50) | -2.75 (5.51) | 0.57 † |
| VEGF | -12.20 (33.93) | -19.66 (48.69) | 0.98 † |
| IP-10 | -69.42 (226.30) | -111.28 (246.90) | 0.79 † |
| PDGF | 82.26 (249.85) | 107.19 (312.54) | 0.61 † |
| Rantes | 852.65 (2356.60) | 974.85 (2298.04) | 0.65 † |
*The sample size is greater than for the main Ki-67 analysis as all patients are included. N = 126: 2 patients in MAG-EPA group dropped out before surgery and 2 patients in placebo group did not have blood collection at prostatectomy. P-value from **independent samples t-test or † FIigner Policello test. MAG-EPA monoacylglyceride-conjugated eicosapentaenoic acid, MD mean difference, RP radical prostatectomy.